Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018

Tyme Technologies (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal year ended March 31, 2018. The Company’s lead clinical program, SM-88, is a novel combination therapy designed to use cellular metabolism and oxidative stress to drive cancer cell death. SM-88 is being evaluated in two ongoing Phase II clinical trials for metastatic pancreatic cancer and prostate cancer.

As quoted in the press release:

“Tyme executed on multiple milestones in the fiscal fourth quarter, including major clinical, operational and financing events,” said Steve Hoffman, Tyme’s Co-Founder and Chief Executive Officer. “We had significant data presentations at two important oncology conferences, started a second large Phase II trial in pancreatic cancer and completed our first underwritten equity financing. We are now fully focused on successfully achieving multiple data milestones over the next 12 months and completing the transformation we began last year.”

Click here to read the full press release.